SID 0002 Myriad Genetics
Listen now
Description
In Myriad's analyst day in NYC on September 14, 2015, management discussed the outlook for several new growth drivers, and it addressed challenges faced in its legacy BRCA1/2 hereditary cancer genetic testing franchise. We explore what's new, the ins and outs of each opportunity, and delve into the intricacies of companion diagnostics.
More Episodes
Mitel has assembled an interesting menu of cloud telephony services for businesses, small to large.
Published 01/18/19
Published 01/18/19
Realty Income has a diversified portfolio by sectors within the single parcel commercial property market. What are the risks of each sector, and how does management approach each?
Published 12/21/18
Links
Twitter
Facebook
Instagram
Patreon
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
